Powerful Biology.  Novel Medicines.  Transformative Impact.

OUR FOCUS

We are working to address the significant unmet medical needs of patients across therapeutic areas and diseases.

Powerful Biology.  Novel Medicines.  Transformative Impact.

PIPELINE HIGHLIGHT

Aldafermin's potential: reverse fibrosis and resolve non-alcoholic steatohepatitis (NASH)

NASH is a serious liver disease affecting millions of people ... and growing.

Powerful Biology.  Novel Medicines.  Transformative Impact.

PIPELINE HIGHLIGHT

NGM621's potential: reducing disease progression in geographic atrophy (GA)

GA is a progressive retinal degenerative disease
impacting over 5 million people worldwide.

Powerful Biology.  Novel Medicines.  Transformative Impact.

BECOME AN NGMer

We love working together and challenging each other to pursue great science that will deliver a big impact for patients.

Curious, creative and driven to make a difference?
Consider NGM to advance your career!

Powerful Biology.  Novel Medicines.  Transformative Impact.

In The News

NGM’s late-breaker presentation of data from our 24-week Phase 2 study of aldafermin was selected ‘Best of ILC’.

View all our presentations at this year’s Digital International Liver Congress™ (ILC).

OUR PIPELINE

We aspire to operate one of the most productive R&D engines in the biopharma industry.

Our broad, diverse pipeline of novel, first-in-class medicines spans multiple therapeutic areas and diseases. Every program focuses on a large market indication with high unmet needs and a common goal: delivering outsized impact for patients.

EXPLORE OUR PIPELINE

We have built our company around core scientific values that frame our approach to drug discovery and development.

Our Core Values

Latest News

View all press releases

Aldafermin for NASH

Significantly improving liver steatosis, inflammation, and fibrosis.

Our lead product, aldafermin (formerly NGM282), is a first-in-class, engineered variant of the human hormone FGF19 that has demonstrated a rapid regression of liver fibrosis and improvement in liver function by targeting multiple pathogenic pathways of NASH.

MORE ABOUT ALDAFERMIN

Working Here

Our People Are Our Platform.

What makes NGM tick? Really smart team members who love working together to pursue great science and share a common drive to deliver a huge impact for patients. We have no hierarchies. We collaborate intensively, embrace risk freely and always swing for the fence.

Join Us
Top